Does INFLIXIMAB, RECOMBINANT Cause Off label use? 21 Reports in FDA Database
Grow Your Own Natural Pharmacy at Home
Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.
According to the FDA Adverse Event Reporting System (FAERS), 21 reports of Off label use have been filed in association with INFLIXIMAB, RECOMBINANT. This represents 8.2% of all adverse event reports for INFLIXIMAB, RECOMBINANT.
21
Reports of Off label use with INFLIXIMAB, RECOMBINANT
8.2%
of all INFLIXIMAB, RECOMBINANT reports
2
Deaths
6
Hospitalizations
How Dangerous Is Off label use From INFLIXIMAB, RECOMBINANT?
Of the 21 reports, 2 (9.5%) resulted in death, 6 (28.6%) required hospitalization, and 1 (4.8%) were considered life-threatening.
Is Off label use Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for INFLIXIMAB, RECOMBINANT. However, 21 reports have been filed with the FAERS database.
What Other Side Effects Does INFLIXIMAB, RECOMBINANT Cause?
Pneumocystis jirovecii pneumonia (29)
Infusion related reaction (18)
Histoplasmosis disseminated (16)
Tuberculosis (15)
Lupus-like syndrome (13)
Pulmonary tuberculosis (12)
Drug ineffective (11)
Pneumonia (11)
Crohn's disease (9)
Disseminated tuberculosis (7)
What Other Drugs Cause Off label use?
RITUXIMAB (39,751)
INFLIXIMAB (34,801)
DENOSUMAB (34,612)
METHOTREXATE (24,020)
VEDOLIZUMAB (21,017)
ETANERCEPT (20,178)
TOCILIZUMAB (18,256)
PREDNISONE (17,867)
LENALIDOMIDE (17,017)
ADALIMUMAB (16,417)
Which INFLIXIMAB, RECOMBINANT Alternatives Have Lower Off label use Risk?
INFLIXIMAB, RECOMBINANT vs INFLUENZA A VIRUS A/CALIFORNIA/7/2009 LIVE ANTIGEN\INFLUENZA A VIRUS A/TEXAS/50/2012 LIVE ANTIGEN\INFLUENZA B VIRUS B/BRISBANE/60/2008 LIVE ANTIGEN\INFLUENZA B VIRUS B/MASSACHUSETTS/2/2012 LIVE ANTIGEN
INFLIXIMAB, RECOMBINANT vs INFLUENZA VIRUS VACCINE
INFLIXIMAB, RECOMBINANT vs INFLUENZA VIRUS VACCINE QUADRIVALENT TYPE A+B
INFLIXIMAB, RECOMBINANT vs INGENOL MEBUTATE
INFLIXIMAB, RECOMBINANT vs INLYTA